New bladder cancer drug enters Head-to-Head trial against standard treatment
NCT ID NCT07374549
Summary
This study compares a new experimental drug called SYS6002 against the standard treatment PADCEV for patients with advanced bladder cancer that has progressed after prior chemotherapy and immunotherapy. About 100 participants will be randomly assigned to receive one of these two treatments to see which works better and is safer. The trial will measure how well tumors shrink, how long the benefits last, and what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.